Back

CA19-9 induces microenvironment remodeling in pancreatic ductal adenocarcinoma

Hsu, J.; Song, H.; Ogawa, S.; Kubota, C. S.; Peck, K. L.; Jacobs, E.; Garcia-Rivera, L.; Zhu, J.; Sui, Y.; Jung, W.; Dai, Y.; Lumibao, J. C.; Bottomley, C. R.; Curtis, K.; Bau, M.; Ku, E.; Kuo, K.; Herrera Morales, A.; Stamp, M.; Rock, A.; Okhovat, S. R.; Hunter, T.; Downes, M.; Evans, R.; Zou, J.; Oh, T. G.; Zheng, Y.; Lowy, A. M.; Tiriac, H.; Kaech, S. M.; Engle, D.

2026-05-26 cancer biology
10.64898/2026.05.22.727290 bioRxiv
Show abstract

Durable therapeutic efficacy remains a major barrier to improving outcomes for patients with pancreatic ductal adenocarcinoma (PDAC). An immunosuppressive tumor microenvironment (TME) is a hallmark of PDAC and has been demonstrated to be a dominant driver of therapeutic resistance. The aberrant glycan CA19-9 is prevalent in PDAC and drives tumor progression, but the paracrine mechanisms by which it contributes to TME remodeling are unknown. To address this, we mapped TME changes and performed functional analyses using a genetically engineered mouse model (GEMM) harboring KrasG12D mutation and inducible CA19-9 expression. Elevation of CA19-9 led to expansion of antigen-presenting cancer associated fibroblasts (apCAFs) and regulatory T cells (Tregs), which can drive immunosuppression. Antibody blockade of CA19 -9 resulted in significant restoration of normal histology and decreased apCAF and Treg populations. We dissected the paracrine signaling mechanisms that drive this TME remodeling in vitro using mouse and human organoid mono- and co-culture models as well as in vivo using GEMMs and syngeneic orthotopic transplantation models. CA19-9 induced IL1a and TGFb expression, reprogramming pancreatic mesothelial cells into apCAFs in vitro, which in turn directly ligated naive Cd4+ T cells resulting in Treg differentiation in co-cultures. Antibody blockade of IL1a and TGFb in mice led to reduced apCAF and Treg differentiation. We previously reported that CA19-9 modification of the secreted Fbln3 protein increased Egfr engagement and now find that the induction of IL1a and TGFb expression by CA19-9 is dependent on Fbln3 hyperactivation of EGFR signaling. Genetic depletion of Fbln3 led to reduced tumor progression and increased Cd8+ T cell infiltration in mice. Together these findings identify a previously unknown signaling axis driving immunosuppressive phenotypes in PDAC, uncovering multiple potential nodes to relieve the immunosuppressive pressures within the PDAC TME.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Cancer Cell
38 papers in training set
Top 0.1%
10.3%
2
Cell Reports
1338 papers in training set
Top 5%
8.1%
3
Gastroenterology
40 papers in training set
Top 0.3%
7.1%
4
Cancer Discovery
61 papers in training set
Top 0.2%
7.1%
5
Developmental Cell
168 papers in training set
Top 3%
6.7%
6
Gut
36 papers in training set
Top 0.1%
6.3%
7
Nature Communications
4913 papers in training set
Top 34%
4.8%
50% of probability mass above
8
Immunity
58 papers in training set
Top 1%
4.3%
9
eLife
5422 papers in training set
Top 21%
4.1%
10
Nature Genetics
240 papers in training set
Top 2%
3.5%
11
Journal of Experimental Medicine
106 papers in training set
Top 1%
3.0%
12
JCI Insight
241 papers in training set
Top 2%
2.6%
13
Cancer Research
116 papers in training set
Top 2%
2.1%
14
Journal of Clinical Investigation
164 papers in training set
Top 3%
1.8%
15
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 33%
1.7%
16
Nature Cancer
35 papers in training set
Top 0.8%
1.7%
17
Genes & Development
90 papers in training set
Top 0.5%
1.6%
18
Science
429 papers in training set
Top 16%
1.5%
19
Cell Stem Cell
57 papers in training set
Top 1%
1.3%
20
Cell
370 papers in training set
Top 13%
1.3%
21
Science Advances
1098 papers in training set
Top 22%
1.3%
22
Clinical Cancer Research
58 papers in training set
Top 1%
1.2%
23
Nature
575 papers in training set
Top 14%
1.1%
24
Cell Metabolism
49 papers in training set
Top 2%
0.9%
25
EMBO Molecular Medicine
85 papers in training set
Top 4%
0.9%
26
Oncogene
76 papers in training set
Top 2%
0.8%
27
Cellular and Molecular Gastroenterology and Hepatology
41 papers in training set
Top 0.6%
0.8%
28
The EMBO Journal
267 papers in training set
Top 5%
0.7%
29
Genome Medicine
154 papers in training set
Top 8%
0.7%
30
Science Translational Medicine
111 papers in training set
Top 7%
0.7%